Calidi Biotherapeutics(US:CLDI) Globenewswire·2025-04-22 12:00Core Insights - Calidi Biotherapeutics Inc. is hosting a webinar on April 24, 2025, to discuss its innovative cancer treatment technologies [1][4] - The event will feature insights from Dr. Guy Travis Clifton, the newly appointed Chief Medical Officer, focusing on stem cell-based delivery platforms for oncolytic viruses [2][3] - Calidi's investigational therapy, CLD-201, has received FDA clearance and is advancing into clinical development for treating solid tumors, including breast cancer, head & neck cancer, and soft tissue sarcoma [3] Company Overview - Calidi Biotherapeutics is a clinical-stage immuno-oncology company specializing in stem cell-based platforms that enhance the immune system's ability to combat cancer [5] - The company’s proprietary technology utilizes allogeneic stem cells to deliver oncolytic viruses, targeting various oncology indications, including high-grade gliomas and solid tumors [5] - Calidi's approach aims to improve the efficacy and safety of cancer treatments, potentially addressing metastatic disease through its dual-targeting strategy [5]